Featured Company News
Stay updated with the latest featured news and developments from leading public companies
Approval Granted: Anfield Receives Official Greenlight from Utah Regulators for Velvet-Wood Mine Construction
Anfield’s Velvet-Wood project receives final state regulatory approval for mine construction. This milestone paves the way for mobilization, development, and increased uranium production in the U.S.
Anfield Provides Positive Update Regarding its Confirmation Drill Program at Its JD-7 Mine
Anfield reports strong interim results from its JD-7 mine confirmation drill program, confirming uranium mineralization and progress toward resource expansion and development.
Former U.S. Congressman to Join Anfield Board
Anfield Energy appoints former U.S. Congressman Jeff Duncan to its Board, bringing extensive energy policy and government experience
Anfield Receives Approval to List on NASDAQ
Anfield Energy gains approval to list on NASDAQ under symbol AEC starting Sept 18, boosting its U.S. visibility, with uranium & vanadium assets and production plans.
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
Revive Therapeutics nears completion of critical nerve agent countermeasure study with Canada’s DND, unlocking major stockpiling potential.
Anfield Files Notice of Intent to Conduct Drill Program As It Expands Its Hub-And-Spoke Uranium and Vanadium Production Model
Anfield Energy has filed a Notice of Intent to start a 20‑hole, 8,000-ft drill program at JD‑7 in Colorado, aiming to grow its hub‑and‑spoke uranium and vanadium model.
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
Revive Therapeutics updates on its Bucillamine study for nerve agent exposure, with results expected by June 2025, aiming for FDA and Health Canada approvals.
Anfield Submits NASDAQ Listing Application and US Registration Statement
Anfield Energy has submitted its NASDAQ listing application and SEC Form 20-F, advancing plans to become a near-term U.S. uranium producer.
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
Revive Therapeutics to investigate Bucillamine for its potential in Cancer Treatment